Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial

Autor: Edoardo Pennesi, Erica Brivio, Anneke C. J. Ammerlaan, Yilin Jiang, Vincent H. J. van der Velden, H. Berna Beverloo, Barbara Sleight, Franco Locatelli, Benoit Brethon, Claudia Rossig, Gernot Engstler, Anna Nilsson, Benedicte Bruno, Arnaud Petit, Bella Bielorai, Carmelo Rizzari, Fanny Rialland, Alba Rubio-San-Simón, Francisco J. Bautista Sirvent, Cristina Diaz-de-Heredia, Susana Rives, Christian M. Zwaan

Publikováno v: Haematologica, Vol 999, Iss 1 (2024)

Inotuzumab Ozogamicin (InO) is a CD22-directed antibody conjugated with calicheamicin. The Phase 1B of the ITCC-059 trial tested InO combined with chemotherapy in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Relapsed /refractory

Externí odkaz: https://doaj.org/article/c0f7af8ee2a94f19b2f8e805c1f3d42c

Association of Altered Plasma Lipidome with Disease Severity in COVID-19 Patients

Autor: Zhengzheng Zhang, Naama Karu, Alida Kindt, Madhulika Singh, Lieke Lamont, Adriaan J. van Gammeren, Anton A. M. Ermens, Amy C. Harms, Lutzen Portengen, Roel C. H. Vermeulen, Willem A. Dik, Anton W. Langerak, Vincent H. J. van der Velden, Thomas Hankemeier

Publikováno v: Biomolecules, Vol 14, Iss 3, p 296 (2024)

The severity of COVID-19 is linked to an imbalanced immune response. The dysregulated metabolism of small molecules and bioactive lipids has also been associated with disease severity. To promote understanding of the disease biochemistry and provide

Externí odkaz: https://doaj.org/article/0adcf97b6f124302ab3467c687420a55

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial

Autor: Stefania Oliva, Davine Hofste op Bruinink, Lucie Rihova, Mattia D’Agostino, Lucia Pantani, Andrea Capra, Bronno van der Holt, Rossella Troia, Maria Teresa Petrucci, Tania Villanova, Pavla Vsianska, Romana Jugooa, Claudia Brandt-Hagens, Milena Gilestro, Massimo Offidani, Rossella Ribolla, Monica Galli, Roman Hajek, Francesca Gay, Michele Cavo, Paola Omedé, Vincent H. J. van der Velden, Mario Boccadoro, Pieter Sonneveld

Publikováno v: Blood Cancer Journal, Vol 11, Iss 6, Pp 1-9 (2021)

Abstract Minimal residual disease (MRD) by multiparameter flow cytometry (MFC) is the most effective tool to define a deep response in multiple myeloma (MM). We conducted an MRD correlative study of the EMN02/HO95 MM phase III trial in newly diagnose

Externí odkaz: https://doaj.org/article/fff4989bfcb448fa8d1e3442a6743211

Severe COVID-19 Is Characterised by Perturbations in Plasma Amines Correlated with Immune Response Markers, and Linked to Inflammation and Oxidative Stress

Autor: Naama Karu, Alida Kindt, Adriaan J. van Gammeren, Anton A. M. Ermens, Amy C. Harms, Lutzen Portengen, Roel C. H. Vermeulen, Willem A. Dik, Anton W. Langerak, Vincent H. J. van der Velden, Thomas Hankemeier

Publikováno v: Metabolites, Vol 12, Iss 7, p 618 (2022)

The COVID-19 pandemic raised a need to characterise the biochemical response to SARS-CoV-2 infection and find biological markers to identify therapeutic targets. In support of these aims, we applied a range of LC-MS platforms to analyse over 100 plas

Externí odkaz: https://doaj.org/article/073d6edbccc042028a63a7fd135e0ee6

Multiparameter flow cytometry in the evaluation of myelodysplasia

Autor: Anna Porwit, Marie C. Béné, Carolien Duetz, Sergio Matarraz, Uta Oelschlaegel, Theresia M. Westers, Orianne Wagner‐Ballon, Shahram Kordasti, Peter Valent, Frank Preijers, Canan Alhan, Frauke Bellos, Peter Bettelheim, Kate Burbury, Nicolas Chapuis, Eline Cremers, Matteo G. Della Porta, Alan Dunlop, Lisa Eidenschink‐Brodersen, Patricia Font, Michaela Fontenay, Willemijn Hobo, Robin Ireland, Ulrika Johansson, Michael R. Loken, Kiyoyuki Ogata, Alberto Orfao, Katherina Psarra, Leonie Saft, Dolores Subira, Jeroen te Marvelde, Denise A. Wells, Vincent H. J. van der Velden, Wolfgang Kern, Arjan A. van de Loosdrecht

Publikováno v: Cytometry. Part B-Clinical Cytometry, 104, 1, pp. 27-50
Cytometry. Part B-Clinical Cytometry, 104, 27-50
Porwit, A, Béné, M C, Duetz, C, Matarraz, S, Oelschlaegel, U, Westers, T M, Wagner-Ballon, O, Kordasti, S, Valent, P, Preijers, F, Alhan, C, Bellos, F, Bettelheim, P, Burbury, K, Chapuis, N, Cremers, E, Della Porta, M G, Dunlop, A, Eidenschink-Brodersen, L, Font, P, Fontenay, M, Hobo, W, Ireland, R, Johansson, U, Loken, M R, Ogata, K, Orfao, A, Psarra, K, Saft, L, Subira, D, te Marvelde, J, Wells, D A, van der Velden, V H J, Kern, W & van de Loosdrecht, A A 2023, ' Multiparameter flow cytometry in the evaluation of myelodysplasia : Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group ', Cytometry Part B-Clinical Cytometry, vol. 104, no. 1, pp. 27-50 . https://doi.org/10.1002/cyto.b.22108

Contains fulltext : 290820.pdf (Publisher’s version ) (Open Access) Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49ad55dec7b7811b97d7a4dba75e8123
http://www.scopus.com/inward/record.url?scp=85144283609&partnerID=8YFLogxK